Journal
EMERGING MICROBES & INFECTIONS
Volume 9, Issue 1, Pages 2269-2277Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1830715
Keywords
SARS-CoV-2; VSV; replication-competent; neutralization assay; entry
Categories
Funding
- National Key Plan for Scientific Research and Development of China [2016YFD0500303]
- National Science and Technology Major Project [2018ZX10101004]
- National Natural Science Foundation of China [81871687]
Ask authors/readers for more resources
Replication-competent vesicular stomatitis virus (VSV)-based recombinant viruses are useful tools for studying emerging and highly pathogenic enveloped viruses in level 2 biosafety facilities. Here, we used a replication-competent recombinant VSVs (rVSVs) encoding the spike (S) protein of SARS-CoV-2 in place of the original G glycoprotein (rVSV-eGFP-SARS-CoV-2) to develop a high-throughput entry assay for SARS-CoV-2. The S protein was incorporated into the recovered rVSV-eGFP-SARS-CoV-2 particles, which could be neutralized by sera from convalescent COVID-19 patients. The recombinant SARS-CoV-2 also displayed entry characteristics similar to the wild type virus, such as cell tropism and pH-dependence. The neutralizing titers of antibodies and sera measured by rVSV-eGFP-SARS-CoV-2 were highly correlated with those measured by wild-type viruses or pseudoviruses. Therefore, this is a safe and convenient screening tool for SARS-CoV-2, and it may promote the development of COVID-19 vaccines and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available